Lung inflammation and simulated airway resistance in infants with cystic fibrosis

Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis

BACKGROUND

The drug combination elexacaftor-tezacaftor-ivacaftor (ETI) proved highly effective in the improvement of the respiratory symptoms, the percentage of predicted forced expiratory volume in 1 s (FEV1), and to reduce rates of pulmonary exacerbations in people with cystic fibrosis (CF) with at least one F508del mutation. The objectives of the study were to evaluate the impact of ETI on the daily treatment burden due to patient decision and the evolution of lung function parameters at 6 months of treatment in real life.

METHODS

A single-center observational study was realized including adult patients starting ETI therapy from March 10, 2020 to April 5, 2022. Clinical characteristics were collected at initiation (T0) and at 6 months (T6) of treatment. Outcome measures included names and number of chronic daily medications, respectively lung function parameters: FEV1, forced vital capacity (FVC), FEV1/FVC ratio, peak expiratory flow (PEF), forced expiratory flow at 25-75% of FVC (FEF25-75), β-angle and FEF50/PEF ratio.

RESULTS

Sixty-five patients were included with a mean age of 29.4 ± 8.5 years old, 48% of them F508del homozygous previously treated by lumacaftor-ivacaftor. At T6, the median number of daily medications decreased from 13 [2-24] to 9 [1-19] (p < 0.001). All the studied functional respiratory parameters were improved: FEV1 +18%, FVC +14%, FEF25-75% + 18% (all p < 0.001), as well the airflow obstruction: FEV1/FVC +6%, FEF50/PEF by 0.1 ± 0.1 and β-angle by 10° ± 13° (all p ≤ 0.007).

CONCLUSION

ETI therapy can reduce the daily treatment burden in real-life at 6 months of treatment, increase a large number of lung function parameters and improve airflow obstruction.

Computational, Ex Vivo, and Tissue Engineering Techniques for Modeling Large Airways

The large airways are a critical component of the respiratory tree serving both an immunoprotective role and a physiological role for ventilation. The physiological role of the large airways is to move a large amount of air to and from the gas exchange surfaces of the alveoli. This air becomes divided along the respiratory tree as it moves from the large airways to smaller airways, bronchioles, and alveoli. The large airways are incredibly important from an immunoprotective role as the large airways are an early line of defense against inhaled particles, bacteria, and viruses. The key immunoprotective feature of the large airways is mucus production and mucociliary clearance mechanism. Each of these key features of the lung is important from both a basic physiology perspective and an engineering perspective for regenerative medicine. In this chapter, we will cover the large airways from an engineering perspective to highlight existing models of the large airways as well as future directions for modeling and repair.